Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (death) · people with cancer pain
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether oral iron changes serious adverse events compared with inactive control (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
Numbers of children with serious adverse events · children with egg allergy
1 finding from 1 review
Adverse events experienced at short or long term ‐ Serious adverse events 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in adverse events experienced at short or long term ‐ Serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
no estimate extracted
Studies not reported
Very low